Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
Yarden, Yosef
Elkabets, Moshe
161,19 €(IVA inc.)
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
- ISBN: 978-3-319-67930-3
- Editorial: Springer
- Encuadernacion: Cartoné
- Páginas: 240
- Fecha Publicación: 06/03/2018
- Nº Volúmenes: 1
- Idioma: Inglés